UBS Group
CURX

UBS Group’s Curanex Pharmaceuticals CURX Stock Holding History

UBS Group’s Portfolio CURX Stock Details CURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$400 Sell
75
-325
-81% -$2.37K ﹤0.01% 9875
2026
Q1 		$4.08K Sell
400
-250
-38% -$1.88K ﹤0.01% 8992
2025
Q4 		$4.3K Sell
650
-2,576
-80% -$28.3K ﹤0.01% 8857
2025
Q3 		$46.5K Buy
+3,226
New +$292K ﹤0.01% 7619

Other funds holding CURX

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group's CURX Position: Q2 2026 in Review

UBS Group reduced its Curanex Pharmaceuticals (CURX) stake by 81% in Q2 2026, selling an estimated $2.37K and leaving 75 shares worth $400. The position accounts for ﹤0.01% of the portfolio, ranked #9875.

UBS Group first reported a position in CURX in Q3 2025 and has held it in 4 quarters since. The position peaked at $46.5K in Q3 2025. 11 funds tracked by Wall St. Rank hold CURX as of Q2 2026.

  • UBS Group held 75 shares of Curanex Pharmaceuticals worth $400 as of Q2 2026.
  • UBS Group sold 325 Curanex Pharmaceuticals shares in Q2 2026, an estimated $2.37K.
  • Curanex Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9875 holding.
  • UBS Group first reported a position in Curanex Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • UBS Group's Curanex Pharmaceuticals position peaked at $46.5K in Q3 2025.
  • 11 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.